Answer
Futibatinib (Lytgobi) monotherapy is indicated for adults with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement that has progressed after at least one prior line of systemic therapy.
Sources for this answer
- Lytgobi 4 mg film-coated tabletsTaiho Pharma Europe Ltd · emc · SmPC §4.1 Therapeutic Indications · Version 3Document updated
Sources checked